STOCKHOLM, July 11, 2019 /PRNewswire/ -- BioArctic AB (publ)
(Nasdaq Stockholm: BIOA B) announced today that presentations
related to BAN2401 will be given at the Alzheimer's Association
International Conference® 2019 (AAIC®) to be held July 14-18 in Los
Angeles, USA.
In addition to the presentations, BioArctic's partner Eisai will
sponsor an interactive satellite symposium focusing on the
rationale and opportunities for drug development in preclinical
Alzheimer's disease – clinically normal people with increased
cerebral amyloid deposition who are at risk for developing
Alzheimer's disease. The symposium will take place Tuesday, July 16.
Presentations related to BAN2401 during AAIC® 2019:
Presentation
ID
|
Topic
|
Date and Time
(Pacific Daylight Time)
|
Abstract ID:
35340
Poster P4-704
|
BAN2401 binding to
soluble aggregated amyloid-beta species
Presenter: Dr. Lars Lannfelt, Uppsala University and
BioArctic
|
Wednesday, July
17
1:00 – 2:00 PM
|
Abstract ID:
35653
Poster P4-657
|
Population
Pharmacokinetic/Pharmacodynamic Analyses of BAN2401 In Patients
with Early Alzheimer's Disease: Correlation of BAN2401 Exposure,
PET Standard Uptake Value Ratio, and Cognitive Outcomes
|
Wednesday, July
17
1:00 – 2:00 PM
|
Abstract ID:
35585
Oral presentation
DT-01-01
|
BAN2401 In Early
Alzheimer's Disease: Neurodegeneration Biomarker Analysis From
Randomized Phase 2 Study
|
Wednesday, July
17
2:00 – 2:15 PM
|
This release discusses investigational uses of an agent in
development and is not intended to convey conclusions about
efficacy or safety. There is no guarantee that any investigational
uses of such product will successfully complete clinical
development or gain health authority approval.
This information was submitted for publication at
07:30 a.m. CET on July 11, 2019.
Notes to editors
About BAN2401
BAN2401 is a humanized monoclonal antibody that is the result of
a strategic research alliance between BioArctic and Eisai. BAN2401
has a unique binding profile and selectively binds to and
eliminates soluble, toxic amyloid-beta aggregates (protofibrils)
that are thought to contribute to the neurodegenerative process in
Alzheimer's disease. As such, BAN2401 has the potential to have an
effect on the disease pathology and to slow down the progression of
the disease. Eisai obtained the global rights to study, develop,
manufacture and market BAN2401 for the treatment of Alzheimer's
disease pursuant to an agreement concluded with BioArctic in
December 2007. In March 2014, Eisai and Biogen entered into a joint
development and commercialization agreement for BAN2401. Currently,
a global confirmatory Phase 3 clinical study (Clarity AD) of
BAN2401 in patients with early Alzheimer´s disease is underway.
According to Eisai, the final readout of the primary endpoint of
the study is targeted for 2022.
About the collaboration between BioArctic and Eisai
Since 2005, BioArctic has long-term collaboration with Eisai
regarding the development and commercialization of drugs for the
treatment of Alzheimer's disease. The most important agreements are
the development and commercialization agreement on the BAN2401
antibody, which was signed in December
2007, and the development and commercialization agreement on
the antibody BAN2401 back-up for Alzheimer's disease, which was
signed in May 2015. Eisai is
responsible for the clinical development, application for market
approval and commercialization of the products for Alzheimer's
disease. BioArctic has no development costs for BAN2401 in
Alzheimer's disease.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma
company focusing on disease-modifying treatments and reliable
biomarkers and diagnostics for neurodegenerative diseases, such as
Alzheimer's disease and Parkinson's disease. The company also
develops a potential treatment for Complete Spinal Cord Injury.
BioArctic focuses on innovative treatments in areas with high unmet
medical needs. The company was founded in 2003 based on innovative
research from Uppsala University,
Sweden. Collaborations with
universities are of great importance to the company together with
its strategically important global partners in the Alzheimer
(Eisai) and Parkinson (AbbVie) projects. The project portfolio is a
combination of fully funded projects run in partnership with global
pharmaceutical companies and innovative in-house projects with
significant market- and out-licensing potential. BioArctic's
B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For
more information about BioArctic, please visit
www.bioarctic.com.
About Eisai Co., Ltd.
Eisai Co., Ltd. is a leading global research and
development-based pharmaceutical company headquartered in
Japan. Eisai defines their
corporate mission as "giving first thought to patients and their
families and to increasing the benefits health care provides,"
which Eisai calls their human health care (hhc)
philosophy. With approximately 10,000 employees working across the
global network of R&D facilities, manufacturing sites and
marketing subsidiaries, Eisai strives to realize their hhc
philosophy by delivering innovative products to address unmet
medical needs, with a particular focus in the strategic areas of
Neurology and Oncology.
Eisai has been working to establish a social environment that
involves patients in each community in cooperation with various
stakeholders including the government, healthcare professionals and
care workers, and is estimated to have held over ten thousand
dementia awareness events worldwide. As a pioneer in the field of
dementia treatment, Eisai is striving to not only develop next
generation treatments but also to develop diagnosis methods and
provide solutions. For more information about Eisai Co., Ltd.,
please visit www.eisai.com.
For more information, please contact:
Gunilla Osswald, PhD, CEO,
BioArctic AB
E-mail: gunilla.osswald@bioarctic.se
Telephone: + 46 8 695 69 30
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/bioarctic/r/bioarctic-and-eisai-to-present-ban2401-at-the-alzheimer-s-association-international-conference-2019,c2861238
The following files are available for download:
https://mb.cision.com/Main/9978/2861238/1076033.pdf
|
Release
|